Who are Probiotic Combination Cap/Tab's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): "Metronidazole" and "Lactobacillus", Mixture of three Bifidobacteria, Clotrimazole vaginal tablets+ Lactobacillus, INF108F probiotic, Lactobacillus plantarum, Lactobacillus casei variety rhamnosus granules.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/probiotic-combination-cap-tab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Probiotic Combination Cap/Tab — Competitive Intelligence Brief

Probiotic Combination Cap/Tab (Probiotic Combination Cap/Tab) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Probiotic. Area: Gastroenterology / Immunology.

phase 3 Probiotic Gastroenterology / Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Probiotic Combination Cap/Tab (Probiotic Combination Cap/Tab) — Seoul National University Bundang Hospital. A probiotic combination restores beneficial gut microbiota to improve intestinal health and immune function.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Probiotic Combination Cap/Tab TARGET	Probiotic Combination Cap/Tab	Seoul National University Bundang Hospital	phase 3	Probiotic
"Metronidazole" and "Lactobacillus"	"Metronidazole" and "Lactobacillus"	Peking University Shenzhen Hospital	marketed	Antibiotic + Probiotic combination
Mixture of three Bifidobacteria	Mixture of three Bifidobacteria	Federico II University	marketed	Probiotic
Clotrimazole vaginal tablets+ Lactobacillus	Clotrimazole vaginal tablets+ Lactobacillus	Peking University Shenzhen Hospital	marketed	Antifungal + probiotic combination	Fungal lanosterol 14α-demethylase (CYP51); Lactobacillus competitive exclusion and microbiota restoration
INF108F probiotic	INF108F probiotic	Massachusetts General Hospital	marketed	Live biotherapeutic product (probiotic)
Lactobacillus plantarum	Lactobacillus plantarum	Shenzhen People's Hospital	marketed	Probiotic
Lactobacillus casei variety rhamnosus granules	Lactobacillus casei variety rhamnosus granules	Seoul National University Hospital	marketed	Probiotic / Live biotherapeutic product

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Probiotic class)

BioBalance Corporation · 1 drug in this class
Biocodex · 1 drug in this class
CD Pharma India Pvt. Ltd. · 1 drug in this class
CHU de Quebec-Universite Laval · 1 drug in this class
Chuncheon Sacred Heart Hospital · 1 drug in this class
Dow University of Health Sciences · 1 drug in this class
Federico II University · 1 drug in this class
Fundación Hospital de Pediatría Prof. Dr. Juan P. Garrahan · 1 drug in this class
GWT-TUD GmbH · 1 drug in this class
Aga Khan University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Probiotic Combination Cap/Tab — Competitive Intelligence Brief. https://druglandscape.com/ci/probiotic-combination-cap-tab. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab